Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of intermittent rimegepant for prevention of menstrual migraine
jRCT2031250041Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Catamenial Migraine and migraine comparing Rimegepant intermittent prevention with Placebo intermittent prevention (2 arms). Primary endpoint: Mean change in migraine days per 5-day perimenstrual period. Started Jun 2025; status: active, not recruiting.
02
Drugs
rimegepant
03
Conditions
Catamenial Migrainemigraine
Beyond the preview
Go deeper on jRCT2031250041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250041.